Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

@article{Horek2006MechanismOA,
  title={Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia},
  author={Jiř{\'i} Hor{\'a}{\vc}ek and Věra Buben{\'i}kov{\'a}-Vale{\vs}ov{\'a} and Milan Kope{\vc}ek and Tom{\'a}{\vs} P{\'a}len{\'i}{\vc}ek and Colleen A. Dockery and Pavel Mohr and Cyril H{\"o}schl},
  journal={CNS Drugs},
  year={2006},
  volume={20},
  pages={389-409}
}
Atypical antipsychotics have greatly enhanced the treatment of schizophrenia. The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained. This article summarises the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiology of schizophrenia.When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant. The optimal occupancy of dopamine D2… 
Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis
TLDR
A critical review of the pharmacology of atypical APD is provided, especially from the viewpoint of receptor binding profiles and neurotransmitter regulations as well as neuroprotection and neurogenesis, to suggest that GSK‐3β might play a role in the action mechanisms of atymic APD, in both the 5‐HT‐dependent and BDNF‐dependent mechanisms.
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
TLDR
An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided.
Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia
  • M. Fraley
  • Medicine, Biology
    Expert opinion on therapeutic patents
  • 2009
TLDR
This review focuses on the structures and biological activities of small molecule potentiators of mGluR2 that appeared in the patent literature between 2006 and early 2009 and indicates that development candidates have likely been nominated.
Emerging treatments in the management of schizophrenia – focus on sertindole
TLDR
In controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia.
The Ideal Antipsychotic: Hybrid between Typical Haloperidol And the Atypical Clozapine Antipsychotic
TLDR
The design of a “hybrid structure” having the desired properties of haloperidol and clozapine is proposed, with the intention being to find an optimal antipsychotic agent that exerts efficient therapeutic effects against both positive and negative symptoms of psychosis causing least possible side effects, such as in monotherapy.
Exploring the kinetic selectivity of antipsychotics for dopamine D2 and 5-HT2A receptors: implications for the prevalence of EPS and receptor occupancy
TLDR
There is room for the development of novel kinetically optimised antipsychotic agents that modulate both serotonergic and dopamine function in a manner beneficial in the treatment of this chronic and debilitating disease.
A review of the adverse side effects associated with antipsychotics as related to their efficacy.
TLDR
There is reason to believe that a more personalised approach to antipsychotic treatment should be considered and screening for risk factors, screening for the appearance of side effects, as well as good communication with patients about the side effects and other options available are important tasks for clinicians to optimise concordance with medication.
Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders
...
...

References

SHOWING 1-10 OF 242 REFERENCES
Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.
  • B. Dean, E. Scarr
  • Psychology, Medicine
    Current drug targets. CNS and neurological disorders
  • 2004
TLDR
A growing understanding of the mechanisms of clozapine and other atypical antipsychotic drugs suggests that both partial and inverse agonism, as well as receptor antagonism, at specific neurotransmitter receptors is required to give full therapeutic benefits.
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
TLDR
This work has found that the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripIPrazole is no higher than with placebo.
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Serotonin receptors : their key role in drugs to treat schizophrenia
Atypical antipsychotics — serotonergic mechanisms but don't forget dopamine
TLDR
It seems reasonable to suppose that atypical antipsychotic drugs such as clozapine are achieving their therapeutic actions via blockade of D2-like receptors, based on the observation that the affinity at D2 receptors is too low for there to be high levels of binding at the levels of free clozAPine observed in the plasma at therapeutic doses.
Antipsychotic drugs, dopamine receptors, and schizophrenia
  • P. Seeman
  • Psychology, Medicine
    Clinical Neuroscience Research
  • 2001
Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality
  • U. Heresco-Levy
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2003
Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.
  • S. Kapur, P. Seeman
  • Psychology, Medicine
    Journal of psychiatry & neuroscience : JPN
  • 2000
TLDR
The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor, and drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission.
The dopamine D4 receptors and mechanisms of antipsychotic atypicality
  • A. H. Wong, H. V. Tol
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2003
...
...